Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis-Reference-Cited by-同舟云学术

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

Published:2023-03 Issue:2 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Hauser Stephen L.¹,Bar-Or Amit¹,Weber Martin S.¹,Kletzl Heidemarie¹,Günther Andreas¹,Manfrini Marianna¹,Model Fabian¹,Mercier Francois¹,Petry Claire¹,Wing Qing¹,Koendgen Harold¹,Smith Terence¹,Kappos Ludwig¹

Affiliation:

1. From the UCSF Weill Institute for Neurosciences and Department of Neurology, University of California, San Francisco (S.L.H.); Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics (A.B.-O.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Institute of Neuropathology and Department of Neurology (M.S.W.), Universitätsmedizin Göttingen Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP, Göttingen, Germany; F. Hoffmann-La Roche...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200094

Reference36 articles.

1. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

2. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

3. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

4. Five years of ocrelizumab in relapsing multiple sclerosis

5. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Concentrations of Monomethyl Fumarate in Patients with Multiple Sclerosis: Result from Routine Health Care;CNS & Neurological Disorders - Drug Targets;2024-12

2. A personalized approach for anti-CD20 therapies in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

3. The neuropathobiology of multiple sclerosis;Nature Reviews Neuroscience;2024-05-24

4. The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis;Journal of Neurology;2024-05-23

5. Memory B cell–guided extended interval dosing of ocrelizumab in multiple sclerosis;Multiple Sclerosis Journal;2024-05-20